UroGen Pharma (URGN) Interest Expenses (2016 - 2026)

UroGen Pharma (URGN) has reported Interest Expenses for 11 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses rose 2400.0% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 446.18% YoY) and the FY2025 annual result came in at $198.4 million, up 17.73% from the prior year.
• Interest Expenses improved to $5.5 million in Q1 2026 per URGN's latest filing, from $244000.0 in the prior quarter.
• Over the last five years, Interest Expenses for URGN reached as high as $6.0 million in Q3 2025 and fell as low as $219000.0 in Q4 2024.
• A 5-year average of $2.0 million and a median of $1.3 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses surged 89233.33% — and 2024, when it sank 89.65%.
• Year by year, Interest Expenses stood at $294000.0 in 2022, then retreated by 1.02% to $291000.0 in 2023, then fell by 24.74% to $219000.0 in 2024, then advanced by 11.42% to $244000.0 in 2025, then soared by 2154.1% to $5.5 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $5.5 million, $244000.0, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.